GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Egfr | affects response to substance | ISO | EGFR (Homo sapiens) | 6480464 | CTD | EGFR protein affects the susceptibility to Erlotinib Hydrochloride; EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride | PMID:21080748 | Egfr | decreases activity | ISO | EGFR (Homo sapiens) | 6480464 | CTD | Erlotinib Hydrochloride results in decreased activity of EGFR protein | PMID:12907618 PMID:21080748 PMID:22751098 PMID:23440206 | Egfr | decreases expression | ISO | EGFR (Homo sapiens) | 6480464 | CTD | Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form | PMID:30136359 | Egfr | decreases phosphorylation | ISO | EGFR (Homo sapiens) | 6480464 | CTD | Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein | PMID:16891461 PMID:23099361 PMID:23894143 | Egfr | decreases response to substance | ISO | EGFR (Homo sapiens) | 6480464 | CTD | EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride | PMID:16407879 | Egfr | multiple interactions | ISO | EGFR (Homo sapiens) | 6480464 | CTD | [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]; Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein; Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein | PMID:19168569 PMID:21541241 PMID:21787763 PMID:22223758 PMID:23548265 PMID:25625231 PMID:26455392 PMID:28101945 PMID:30364229 PMID:30623574 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |